Why the Race Oncology (ASX:RAC) share price is racing higher

Why the Race Oncology (ASX:RAC) share price is racing higher


Why the Race Oncology (ASX:RAC) share price is racing higher
Ken Hall | April 28, 2021 10:49am |
More on:
The 
Race Oncology Ltd (ASX: RAC) share price is climbing today after an update from the Aussie healthcare company.
Why is the Race Oncology share price climbing?
Race Oncology announced that it has entered into a collaborative preclinical research program with The University of Newcastle. The purpose of the program is to investigate the heart safety Bisantrene offers over current anthracycline therapeutics. 
Bisantrene is Race Oncology’s Phase 2/3 cancer drug that is a “potent inhibitor” of the Fatso/Fat mass and obesity-associated (FTO) protein. The possible role of FTO inhibition in Bisantrene’s lack of cardiotoxicity will be a primary focus of the new project.

Related Keywords

Australia , Aussie , Daniel Tillett , Aaron Sverdlov , Scott Phillips , Doan Ngo , Race Oncology Ltd , University Of Newcastle , Race Oncology , Three Pillar , Scientific Officer Dr Daniel Tillett , Motley Fool Share Advisor , ஆஸ்திரேலியா , ஆஸி , டேனியல் டிலெட் , ஸ்காட் பிலிப்ஸ் , டோந் ங்கோ , இனம் புற்றுநோயியல் லிமிடெட் , பல்கலைக்கழகம் ஆஃப் நியூகேஸில் , இனம் புற்றுநோயியல் , மூன்று தூண் ,

© 2025 Vimarsana